vs

Side-by-side financial comparison of Esquire Financial Holdings, Inc. (ESQ) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $40.5M, roughly 1.9× Esquire Financial Holdings, Inc.). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 15.0%).

Esquire Financial Holdings, Inc. is a U.S.-headquartered bank holding company that provides comprehensive commercial and consumer banking products and services. Its core offerings include deposit accounts, business loans, mortgage services, and wealth management solutions, primarily serving small to medium enterprises, legal industry professionals, and local retail clients.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

ESQ vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.9× larger
PBYI
$75.5M
$40.5M
ESQ
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
15.0%
ESQ

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESQ
ESQ
PBYI
PBYI
Revenue
$40.5M
$75.5M
Net Profit
$12.2M
Gross Margin
69.3%
Operating Margin
22.7%
Net Margin
30.2%
Revenue YoY
27.7%
Net Profit YoY
7.0%
EPS (diluted)
$1.40
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESQ
ESQ
PBYI
PBYI
Q1 26
$40.5M
Q4 25
$39.4M
$75.5M
Q3 25
$37.6M
$54.5M
Q2 25
$35.8M
$52.4M
Q1 25
$33.8M
$46.0M
Q4 24
$33.1M
$59.1M
Q3 24
$31.9M
$80.5M
Q2 24
$30.6M
$47.1M
Net Profit
ESQ
ESQ
PBYI
PBYI
Q1 26
$12.2M
Q4 25
$13.5M
Q3 25
$14.1M
$8.8M
Q2 25
$11.9M
$5.9M
Q1 25
$11.4M
$3.0M
Q4 24
$11.8M
Q3 24
$11.4M
$20.3M
Q2 24
$10.5M
$-4.5M
Gross Margin
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Operating Margin
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
44.3%
22.7%
Q3 25
46.5%
17.6%
Q2 25
42.5%
12.7%
Q1 25
45.9%
8.7%
Q4 24
47.4%
22.6%
Q3 24
48.8%
27.4%
Q2 24
46.9%
-4.6%
Net Margin
ESQ
ESQ
PBYI
PBYI
Q1 26
30.2%
Q4 25
34.2%
Q3 25
37.4%
16.2%
Q2 25
33.2%
11.2%
Q1 25
33.8%
6.5%
Q4 24
35.6%
Q3 24
35.6%
25.2%
Q2 24
34.3%
-9.6%
EPS (diluted)
ESQ
ESQ
PBYI
PBYI
Q1 26
$1.40
Q4 25
$1.54
$0.26
Q3 25
$1.62
$0.17
Q2 25
$1.38
$0.12
Q1 25
$1.33
$0.06
Q4 24
$1.35
$0.40
Q3 24
$1.34
$0.41
Q2 24
$1.25
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESQ
ESQ
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$222.2M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$301.3M
$130.3M
Total Assets
$2.4B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESQ
ESQ
PBYI
PBYI
Q1 26
$222.2M
Q4 25
$235.9M
$97.5M
Q3 25
$240.8M
$94.4M
Q2 25
$163.0M
$96.0M
Q1 25
$173.0M
$93.2M
Q4 24
$126.3M
$101.0M
Q3 24
$147.7M
$96.7M
Q2 24
$152.7M
$96.8M
Total Debt
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Stockholders' Equity
ESQ
ESQ
PBYI
PBYI
Q1 26
$301.3M
Q4 25
$289.6M
$130.3M
Q3 25
$279.2M
$115.3M
Q2 25
$263.6M
$104.7M
Q1 25
$250.7M
$97.1M
Q4 24
$237.1M
$92.1M
Q3 24
$232.6M
$71.1M
Q2 24
$217.4M
$48.5M
Total Assets
ESQ
ESQ
PBYI
PBYI
Q1 26
$2.4B
Q4 25
$2.4B
$216.3M
Q3 25
$2.2B
$202.9M
Q2 25
$2.1B
$194.9M
Q1 25
$2.0B
$196.2M
Q4 24
$1.9B
$213.3M
Q3 24
$1.8B
$220.7M
Q2 24
$1.7B
$205.0M
Debt / Equity
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESQ
ESQ
PBYI
PBYI
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
$59.8M
$14.4M
Q3 25
$16.8M
$9.7M
Q2 25
$10.5M
$14.1M
Q1 25
$15.8M
$3.6M
Q4 24
$42.2M
$15.6M
Q3 24
$10.5M
$11.0M
Q2 24
$7.2M
$1.0M
Free Cash Flow
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
$56.7M
$14.4M
Q3 25
$16.2M
$9.7M
Q2 25
$9.3M
$14.1M
Q1 25
$14.7M
$3.6M
Q4 24
$41.5M
$15.6M
Q3 24
$10.5M
$11.0M
Q2 24
$6.9M
$1.0M
FCF Margin
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
143.9%
19.1%
Q3 25
43.2%
17.7%
Q2 25
26.0%
26.8%
Q1 25
43.4%
7.7%
Q4 24
125.5%
26.4%
Q3 24
32.8%
13.7%
Q2 24
22.5%
2.1%
Capex Intensity
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
8.0%
0.0%
Q3 25
1.3%
0.0%
Q2 25
3.2%
0.0%
Q1 25
3.4%
0.1%
Q4 24
2.2%
0.0%
Q3 24
0.2%
0.0%
Q2 24
1.1%
0.0%
Cash Conversion
ESQ
ESQ
PBYI
PBYI
Q1 26
Q4 25
4.44×
Q3 25
1.19×
1.10×
Q2 25
0.88×
2.41×
Q1 25
1.39×
1.21×
Q4 24
3.59×
Q3 24
0.93×
0.54×
Q2 24
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESQ
ESQ

Net Interest Income$34.0M84%
Noninterest Income$6.5M16%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons